help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chandrashekar, V.
Right arrow Articles by Kopchick, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chandrashekar, V.
Right arrow Articles by Kopchick, J. J.
Endocrinology Vol. 140, No. 3 1082-1088
Copyright © 1999 by The Endocrine Society

ARTICLES

Pituitary and Testicular Function in Growth Hormone Receptor Gene Knockout Mice1

Varadaraj Chandrashekar, Andrzej Bartke, Karen T. Coschigano and John J. Kopchick

Department of Physiology, Southern Illinois University School of Medicine (V.C., A.B.), Carbondale, Illinois 62901-6512; and Edison Biotechnology Institute, Molecular and Cellular Biology Program, Ohio University (K.T.C., J.J.K.), Athens, Ohio 45701

Address all correspondence and requests for reprints to: Dr. V. Chandrashekar, Department of Physiology, Life Science II Building, Southern Illinois University School of Medicine, Carbondale, Illinois 62901-6512.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The role of GH in the control of pituitary and testicular function is poorly understood. GH receptor gene knockout (GHR-KO) mice were recently produced. As these mice are good experimental animals to assess the influence of the effects of GH and insulin-like growth factor-I (IGF-I), the present studies were undertaken. Young adult male GHR-KO mice and their normal siblings were tested for fertility and subsequently injected (ip) with saline or GnRH (1 ng/g BW) in saline. Fifteen minutes later, blood was obtained via heart puncture. Plasma IGF-I, PRL, LH, and testosterone concentrations were measured by RIAs. In addition, the testicular testosterone response to LH treatment was evaluated in vitro. The results indicate that the absence of GH receptors (GHRs) was associated with an increase (P < 0.005) in plasma PRL levels, and circulating IGF-I was not detectable. Although the basal plasma LH levels were similar in GHR-KO mice relative to those in their normal siblings, the circulating LH response to GnRH treatment was significantly (P < 0.001) attenuated. Plasma testosterone levels were unaffected by disruption of the GHR gene. However, basal (P < 0.01) and LH-stimulated (P < 0.001) testosterone release from the isolated testes of GHR-KO mice were decreased. The rate of fertility in GHR-KO male mice was also reduced. These results indicate that the lack of GHRs (with GH resistance and lack of IGF-I secretion) induces hyperprolactinemia and alters the effect of GnRH on LH secretion as well as testicular function. Thus, GH and IGF-I influence pituitary and gonadal functions in male mice.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
THE EFFECTS of GH on growth and metabolism have been known for many years, but its role in the control of neuroendocrine and gonadal function in mammals is poorly understood. However, studies have suggested that GH may be involved in ovarian function (1, 2). GH antigens are identified in pituitary cells containing FSH or LH messenger RNAs and in GnRH receptors, indicating that either GH cells are transitory gonadotrophs, or GH is present in these pituitary cells, possibly to control their function (3, 4). Furthermore, GH-binding protein antigens were identified in pituitary cells that contained LH and FSH, indicating a paracrine effect of GH on the function of the gonadotrophs (5). Thus, GH may function as a "cogonadotropin" (3, 4). It has been shown that GH administration to oligospermic men enhances the efficacy of exogenous gonadotropins in the induction of sperm production (6). In men, congenital GH resistance due to mutated GH receptors (Laron syndrome) is associated with a delay in sexual maturation (7, 8), suggesting that GH exerts an important function in reproduction. In addition, results from experimental animals have suggested that GH may play an important role in the control of pituitary and testicular functions. It has been shown that GH treatment of hypophysectomized rats, increases the LH receptor content of the testis (9) and enhances the testicular responsiveness to gonadotropin treatment (10). In adult rats, a lack of GH secretion results in a delay in testicular growth and differentiation of germinal cells (11). In our recent study, we have shown that treatment with GH or biological neutralization of endogenous GH by active immunization against GH alters gonadotropin secretion in adult male rats (12). In addition, we have previously shown that administration of GH to GH-deficient Ames dwarf mice increases plasma LH levels (13), indicating that GH might be involved in the control of gonadotropin secretion. However, Ames dwarf mice are also deficient in PRL and TSH (14, 15) and, therefore, are a less suitable model to study the effects of GH. Recently, GH receptor gene knockout (GHR-KO) mice were produced (16). Although these mice secrete large amounts of GH (16), it is assumed that the effects of the secreted GH are absent due to the lack of GH receptors (GHRs). Therefore, these GHR-KO mice are good experimental animals to test the role of GH in neuroendocrine and gonadal function. In this report we have attempted to identify the alterations in fertility, pituitary, and gonadal function in male GHR-KO mice relative to those in their normal siblings.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Genotype determination of the mice used in the present experiments
The genotype of each mouse was determined by PCR analysis of its genomic DNA using a modified version of the procedure described by Eisen et al. (17). In short, an approximately 0.5-cm piece of tail was digested with 400 µl 1 mg/ml proteinase K in SSTE (1% SDS, 100 mM NaCl, 50 mM Tris, and 15 mM EDTA, pH 8) overnight at 55 C. RNA was then degraded with ribonuclease A, protein was removed by phenol-chloroform-isoamyl alcohol (25:24:1) extraction, and DNA was precipitated with sodium acetate and ethanol and redissolved in 300 µl water. PCR was performed on the genomic DNA samples using a combination of three primers: In3+1 (5'-CCTCCCAGAGAGACTGGCTT-3'), In4–1 (5'-CCCTGAGACCTCCTCAGTTC-3'), and Neo-3 (5'-GCTCGACATTGGGTGGAAACAT-3'). Each PCR sample [50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 2 mM MgCl2, 0.2 mM deoxy (d)-ATP, 0.2 mM dCTP, 0.2 mM dGTP, 0.2 mM TTP, 0.5 µM of each primer, 0.05 U Taq DNA polymerase, and 0.13 µl genomic DNA/µl reaction] was amplified in a Perkin-Elmer GeneAmp 9600 (1 cycle of 95 C for 2 min followed by 30 cycles of 95 C for 15 sec, 58 C for 20 sec, and 72 C for 30 sec) and then electrophoresed through a 1% agarose, 1% Metaphor agarose (FMC, Rockland, ME), 1 x TAE (40 mM Tris, 20 mM acetic acid, and 1 mM EDTA), 0.2 µg/ml ethidium bromide gel. Normal siblings produced a single fragment of about 390 bp, homozygous animals produced two fragments of approximately 220 and 290 bp, and heterozygous animals produced all three fragments.

In our laboratory, we found that there were no differences in body weight, basal plasma LH levels, or the LH response to GnRH treatment between homozygous (+/+) and heterozygous (+/-) normal mice. It has been also reported that these two genotypes are not significantly different in terms of secretion of GH, insulin-like growth factor-I (IGF-I), and GHR/GH-binding protein (16). Therefore, in the present studies data from +/+ and +/- mice were combined for statistical analyses and reported as normal mice.

Animals
GHR-KO mice (-/-) were produced as described previously (16). Adult normal female mice bred in our animal facility were mated with either GHR-KO male mice or male mice with the +/- genotype, and the resulting male GHR-KO mice and non-GHR-KO littermates (normal mice) were used in the present experiments. Mice were housed in a room with a controlled photoperiod of 12 h of light/day (lights on from 0600–1800 h) and a temperature of 22–23 C. Mice were given free access to a nutritionally balanced diet (LabDiet, PMI Feeds, Inc., St. Louis, MO) and tap water. The following experiments were conducted.

Fertility testing
Each GHR-KO or normal male mouse was housed with two young adult virgin females for 10 days immediately preceding the experiments described below. The females were checked daily for birth of litters, and the numbers of live and dead pups were recorded.

In vivo experiment.Male GHR-KO mice and their normal siblings (12–13 weeks of age) were divided into two groups (n = 9–10 mice/group) and treated ip as follows: group 1, saline; and group 2, GnRH in saline (1 ng/g BW; Sigma Chemical Co., St. Louis, MO; lot 106F-58302). We have shown previously that this dose of GnRH is effective in inducing LH secretion in normal mice (13, 18). Fifteen minutes after saline or GnRH injection, blood was obtained via heart puncture under ether anesthesia. Plasma samples were frozen at -20 C until assayed for LH, PRL, IGF-I, and testosterone. The pituitary, testes, and male accessory reproductive organs (seminal vesicles and ventral prostate) were removed and weighed with their secretions. Testes from saline-injected mice were removed and used in the following in vitro experiment.

In vitro experiment. Testes were decapsulated and weighed. The decapsulated testes were cut into small fragments of approximately equal weights. One testicular fragment was used per incubation. Testicular incubations were performed as described previously (13, 19). Briefly, testicular fragments were preincubated in Krebs-Ringer bicarbonate buffer (2 ml) containing 1% glucose for 30 min in a Dubnoff metabolic incubator in an atmosphere of 95% oxygen-5% carbon dioxide at 32 ± 2 C with constant shaking at 100 rpm. At 30 min, the incubation medium was removed and replaced with the same buffer (1.9 ml) containing glucose. In addition, either 0.1 ml saline or 5 ng ovine LH (NIH LH-26) in 0.1 ml saline were added, and incubation was continued for 4 h. Incubations were terminated at 4 h, and the medium was used to determine testosterone levels by RIA.

Hormone assays
The concentrations of LH in plasma were determined by RIA as described previously (13, 18), using reagents generously supplied by Dr. A. F. Parlow, Dr. G. D. Niswender, and the National Hormone and Pituitary Program, NIH (Bethesda, MD). Briefly, rat LH RP-2 reference preparation and ovine LH antiserum (GDN-15) were used in the LH RIA. Various amounts of a plasma pool obtained from intact and castrated mice produced curves parallel to those of various amounts of rat LH reference preparation. Therefore, it is valid to use these reagents to measure LH levels in mice. The sensitivity of this assay was 10 pg/tube. All plasma samples were measured starting on the same day, using the same day diluted reference preparation, antiserum, and repurified hormone trace. The intraassay coefficient of variation was 2.8%.

The plasma PRL concentrations were measured by RIA as we previously described (18). Briefly, mouse PRL reference preparation (AFP-6476C) and mouse PRL antiserum (AFP-131078; both provided by Dr. A. F. Parlow) were used in this PRL assay. All plasma samples were measured starting on the same day, using the same day diluted reference preparation, antiserum, and repurified hormone trace. The sensitivity of this assay was 0.1 ng/tube, and the intraassay coefficient of variation was 4.3%.

Plasma testosterone levels were determined by RIA as described previously (12, 13, 18) with a standard extraction (extracted with the anhydrous diethyl ether) procedure. The sensitivity of this testosterone assay was 5 pg/tube. The mean intraassay coefficient of variation was 2.9%.

Plasma IGF-I concentrations were measured by RIA as described by us and others (13, 20, 21). As the presence of IGF-I-binding proteins in the plasma interferes in the RIA procedure, these proteins were removed from the plasma. Plasma samples were extracted with formic acid and acetone as described previously (20). Because this extraction method does not eliminate all IGF-I-binding proteins present in the plasma (21), acid-acetone extracts were subjected to cryoprecipitation, a procedure described previously (21). The mean recoveries of iodinated IGF-I added to the plasma were 90.5%. The Tris-neutralized plasma extracts were diluted with RIA buffer containing 0.02% protamine sulfate and 0.05% Tween-20. Diluted plasma extracts were used in this RIA. The purified recombinant human IGF-I preparation purchased from Amgen, Inc. (Thousand Oaks, CA) was used as the reference preparation, and human IGF-I (A52–8MH-144; Eli Lilly & Co., Indianapolis, IN) was iodinated and used as trace. Antiserum prepared against human IGF-I (UB2–495; developed by Drs. L. E. Underwood and J. J. Van Wyk, University of North Carolina, Chapel Hill, NC) was used in this RIA. Varying quantities of the mouse plasma extract pool produced a curve parallel to the curve obtained by varying amounts of human IGF-I preparation. Therefore, it is valid to use these human IGF-I RIA reagents to measure IGF-I levels in mouse plasma. The sensitivity of this assay was 32 pg/tube. All plasma extracts were included in the same assay to avoid interassay variability. The intraassay coefficient of variation was 2.4%.

Statistical analysis
Statistical analyses were performed by ANOVA followed by the Student-Newman-Keuls test. Student’s t test was used when the values of two groups were compared. Data on the incidence of male fertility were analyzed by a {chi}2 test.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Body, pituitary, and accessory reproductive organ weights
As expected, the mean body weight of GHR-KO mice was significantly (P < 0.001) lower (12.0 ± 0.4 g) than that of normal controls (26.8 ± 0.4 g). Similarly, there were dramatic (P < 0.001) decreases in the pituitary (0.91 ± 0.06 vs. 1.71 ± 0.07 mg), testicular (111.3 ± 6.4 vs. 211.0 ± 8.3 mg), seminal vesicle (92.5 ± 6.0 vs. 187.1 ± 11.7 mg), and ventral prostate (5.9 ± 0.4 vs. 9.8 ± 0.5 mg) absolute weights in GHR-KO mice relative to those in normal mice.

Fertility
Of 22 normal males, 21 impregnated at least 1 of the normal females with which they were housed and thus were considered fertile. However, only 14 of 19 GHR-KO males were fertile by the same criteria (P < 0.05). As each male was mated with 2 females, we also calculated the percentage of females that became pregnant in each of the groups. Eighty-eight percent of the females housed with normal males and 53% of the females housed with GHR-KO males became pregnant (P < 0.001). Litter size, defined as a mean number of live pups, did not differ between litters sired by normal and GHR-KO males (6.4 ± 0.4 vs. 5.9 ± 0.4 pups). There were also no significant differences in the mean numbers of pups found dead in the 2 groups.

Plasma IGF-I and PRL concentrations
Plasma IGF-I levels were 164.4 ± 8.6 ng/ml in normal siblings, and IGF-I was not detectable in the circulation in GHR-KO mice.

Circulating PRL concentrations were significantly (P < 0.005) increased in GHR-KO mice relative to those in their normal siblings (Fig. 1Go).



View larger version (12K):
[in this window]
[in a new window]
  		Figure 1. Circulating PRL levels in normal and GHR-KO mice. Values are means. Vertical lines represent the SEM. Values without the same letter are at a significance level of at least P < 0.05.

 
Effect of GnRH on LH secretion
Plasma basal LH levels in normal as well as GHR-KO mice were similar. Administration of a single dose of GnRH resulted in a significant (P < 0.001) increase in plasma LH levels in both groups of mice. However, this LH response to GnRH treatment was significantly (P < 0.001) attenuated in GHR-KO mice (3.7-fold increase in GHR-KO mice vs. 15.5-fold increase in normal mice; Fig. 2Go).



View larger version (14K):
[in this window]
[in a new window]
  		Figure 2. Circulating LH levels in normal and GHR-KO mice given either saline or GnRH in saline. Values are means. Vertical lines represent the SEM. Values without the same letter are at a significance level of at least P < 0.05.

 
Plasma testosterone levels and in vitro testosterone response to LH treatment
The basal plasma testosterone levels were similar in GHR-KO mice and their normal siblings. Administration of GnRH, which increased plasma LH levels, resulted in increases (P < 0.001) in circulating testosterone levels in both groups of mice (Fig. 3Go). However, this increase was significantly (P < 0.025) lower in mice lacking GHRs.



View larger version (15K):
[in this window]
[in a new window]
  		Figure 3. Circulating testosterone levels in normal and GHR-KO mice given either saline or GnRH in saline. Values are means. Vertical lines represent the SEM. Values without the same letter are at a significance level of at least P < 0.05.

 
The basal release of testosterone by the saline-treated testes (per mg testis) of GHR-KO mice was significantly (P < 0.01) lower than that in the incubation medium containing the testes obtained from normal siblings (Fig. 4Go). LH treatment resulted in an increase (P < 0.001) in testosterone secretion in the medium containing testes from either group of mice. However, the testosterone response to LH treatment was significantly (P < 0.001) attenuated in incubations containing testes of GHR-KO mice (Fig. 4Go). Similarly, the basal total (per two testes) testosterone release was decreased (P < 0.01) in the testes obtained from GHR-KO mice relative to that in the testes of normal mice. The total testosterone response to LH treatment was also decreased (P < 0.001) in the testes of GHR-KO mice (Fig. 5Go).



View larger version (15K):
[in this window]
[in a new window]
  		Figure 4. In vitro testosterone production (per mg testes). Testicular fragments were obtained from normal or GHR-KO mice and exposed to saline or 5 ng LH in saline. Vertical lines represent the SEM. Values without the same letter are at a significance level of at least P < 0.05.

 


View larger version (13K):
[in this window]
[in a new window]
  		Figure 5. In vitro total testosterone production (per two testes). Testicular fragments were obtained from normal or GHR-KO mice and exposed to saline or 5 ng LH in saline. Vertical lines represent the SEM. Values without the same letter are at a significance level of at least P < 0.05.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Although the role of GH in growth and development is known, its effects on pituitary and testicular functions are unclear. The present studies clearly demonstrate that targeted disruption of the GH receptor gene in addition to altering the growth, exerts major modulatory effects on the control of IGF-I as well as PRL secretion, on the GnRH action on pituitary gland, and on testicular function in mice. The targeted disruption of GHR genes also reduced fertility.

Delayed sexual maturation in female GHR-KO mice has been reported, and mating of GHR-KO females with GHR-KO males resulted in reduced litter size (16). In the present study there was a reduction in the fertility of GHR-KO male mice, possibly due to hyperprolactinemia. In the male mouse, hyperprolactinemia was reported to stimulate sexual behavior (22), and we are not aware of any studies of fertility in hyperprolactinemic male mice. However, it has been shown that hyperprolactinemia results in a slight reduction in fertility in female mice (23). The basal testosterone production in vitro and its response to LH treatment were reduced in GHR-KO mice. As testosterone plays an important role in spermatogenesis, it is possible that sperm production is affected by disruption of the GHR gene, and this may have contributed to reduced fertility in these male mice. Subfertility in little (lit/lit) mice with isolated GH deficiency has been shown to be due to longer mount, intromission, and ejaculation latencies (24). Therefore, alterations in sexual behavior might have affected fertility in GHR-KO mice.

It has been shown that GH secretion is increased (16), and in the present study the circulating IGF-I levels were not detectable in GHR-KO mice. We and others have shown in transgenic mice that expression of the various GH or IGF-I genes is associated with accelerated body growth (18, 25, 26). Induction of hyperprolactinemia increases seminal vesicle weight in mice (27). However, in the present study, despite increased PRL secretion, there were decreases in seminal vesicle and ventral prostate weights in GHR-KO mice. In transgenic mice expressing various GH genes, seminal vesicle weights are increased (28), possibly due to increases in IGF-I secretion (29). A significant reduction in BW and in the weight of accessory reproductive structures of GHR-KO mice is most likely due to the impairment of IGF-I secretion and resistance to the endogenously secreted GH.

Functional deficits of the pituitary-testicular axis and the reduced growth rate in GHR-KO mice could be related. It is known that gonadal steroids can influence growth rate and that experimental alterations in testosterone secretion could change the pattern of GH secretion and consequently affect growth (30). In rats, gonadal steroids may affect growth indirectly by altering the effectiveness of GH by modulating the hepatic GH receptor levels (31). In GHR-KO mice, the absence of GHRs and IGF-I secretion was associated with reduced body weight and testicular function. It would appear that the endogenously secreted testosterone is relatively ineffective in inducing growth in GHR-KO mice. This hypothesis is supported by the finding that testosterone treatment does not stimulate growth in hypophysectomized rats (32). Hence, the reduced body weight is probably not due to the alterations in the pituitary-testicular function in GHR-KO mice, but is most likely due to the absence of GHRs and IGF-I secretion. However, it remains to be determined whether the reduced growth rate and body size are involved in mediating the effects of GH resistance on the neuroendocrine-testicular axis in GHR-KO mice.

The present study is the first to demonstrate that GHR-KO mice are hyperprolactinemic. Our previous study has shown that in transgenic mice expressing the bovine GH gene, PRL secretion is increased (33), and dopamine turnover in the median eminence of these animals is reduced (34). As GHR-KO mice produce large amounts of GH (16), it is conceivable that GH might have influenced the function of the pituitary lactotrophs. It is known that dopamine suppresses PRL secretion (35, 36). Therefore, it is tempting to speculate that the excess GH produced in GHR-KO mice might have suppressed tuberoinfundibular dopaminergic neurons, resulting in increased PRL secretion. However, these animals lack GHRs (16). Therefore, we speculate that the mode of GH action in increasing PRL secretion may have been via a different and unknown mechanism. It has been shown that experimental induction of hyperprolactinemia in adult male DBA/2J mice is associated with increase in circulating LH levels (37, 38). However, in GHR-KO mice, despite the hyperprolactinemic condition, basal plasma LH levels were not affected. This might have been due to either the lack of a direct effect of GH on LH-secreting pituitary cells or the absence of IGF-I secretion. As in mice both excess GH production and GH deficiency are associated with altered PRL secretion (14, 15, 18, 33), it may be not possible to separate direct from PRL-mediated effects of GH in the in vivo situation.

Although basal plasma LH levels were not affected, the LH response to GnRH treatment was significantly decreased in GHR-KO mice. This indicates that in these animals, the GnRH action may be affected due to the absence of IGF-I secretion and that GH by itself is unable to restore the normal effect of GnRH on LH secretion. We have shown in GH-deficient Ames dwarf male mice that induction of IGF-I secretion by GH administration improves the LH response to GnRH treatment (13). The attenuated LH response to GnRH treatment in GHR-KO mice is possibly also due to hyper-prolactinemia. It has been shown that hyperprolactinemia attenuates the effects of GnRH in the rat (39, 40) and suppresses the priming effect of GnRH on LH secretion in normal and hypogonadal mice (41).

The lack of GHRs in GHR-KO mice did not affect basal testosterone secretion, possibly due to the normal amounts of LH secretion. Furthermore, the testes of GHR-KO mice responded to the increased secretion of LH after GnRH administration and increased plasma testosterone concentrations. However, this testosterone response was attenuated in GHR gene-disrupted mice relative to that in normal mice. In addition, basal testosterone secretion by the isolated testis was attenuated in GHR-KO mice. The in vitro study also indicated that the testosterone response to LH treatment by the testes of GHR-KO animals was significantly decreased. These data suggest that the effect of LH is influenced, possibly by the subnormal function of the Leydig cells of the testes of GHR-KO mice. GH treatment to hypophysectomized male rats has been shown to increase the LH receptor content of the testis (9), and induction of hyperprolactinemia in mice decreases testicular hCG-binding sites (37), suggesting that GH deficiency and hyperprolactinemic condition in GHR-KO mice might have affected LH receptor number and their function within the testes. It has also been demonstrated that Leydig and Sertoli cells contain IGF-I receptors and that IGF-I can modulate the effects of LH on testosterone secretion by the isolated Leydig cells (42, 43, 44). Therefore, it is possible that due to the lack of production of IGF-I, the full effect of LH on Leydig cells is attenuated in GHR-KO mice.

It has been shown that rat testis contains IGF-I messenger RNA (45, 46). In addition, cultured Sertoli cells and Leydig cells from adult rats secrete IGF-I (47). Treatment of Sertoli cells with FSH and of Leydig cells with LH resulted in increases in IGF-I levels in culture medium (48), suggesting that the secretion of IGF-I might not be dependent on GH. Therefore, it is possible that testicular IGF-I secretion might be normal in GHR-KO mice. However, in the present study the attenuated testosterone response to LH suggests that extratesticular IGF-I may play an important role in the action of LH on testosterone secretion by the testis.

There are some similarities in reproductive characteristics of male GHR-KO mice and those of IGF-I gene-disrupted mice. Similar to GHR-KO mice, the weights of male sex accessory structures were reduced in targeted IGF-I gene-disrupted mice (49). In addition, their circulating testosterone levels were reduced. As in the present study, the in vitro testosterone response to LH treatment was suppressed in the absence of the IGF-I gene (49). However, the IGF-I gene-disrupted mice were infertile. In contrast, fertility is reduced, but not totally suppressed, in GHR-KO mice. The mechanism responsible for the maintenance of fertility in GHR-KO mice is unknown. Furthermore, GH treatment increased IGF-I secretion and consequently elevated the total number of viable spermatozoa in GH-deficient dwarf rats (50) and led to an absence of mating behavior in mice with IGF-I gene null mutation (49), strongly suggesting that IGF-I is important for normal male reproduction.

In conclusion, the present data indicate that targeted disruption of the GHR gene influences the GnRH effect on LH secretion by the pituitary gland, induces hyperprolactinemia, attenuates testicular endocrine function, and reduces fertility in GHR-KO mice. Some of the effects observed in GHR-KO mice might have been due to the lack of IGF-I secretion.


   Acknowledgments
 
We thank Dr. G. D. Niswender, Colorado State University (Fort Collins, CO); Dr. A. F. Parlow, Pituitary Hormone and Antisera Center, Harbor-University of California-Los Angeles Medical Center (Torrance, CA); and the National Hormone and Pituitary Program (Rockville, MD) for generously providing reagents used in testosterone, IGF-I, and pituitary hormone RIAs. Dr. R. B. Bowsher, Eli Lilly & Co. Laboratory for Clinical Research and Eli Lilly & Co. (Indianapolis, IN) generously supplied the recombinant human IGF-I used in the IGF-I RIA.


   Footnotes
 
1 This investigation was supported by NIH Grant HD-20001. Back

Received July 16, 1998.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Blumenfeld Z 1994 Role of growth hormone in ovulation induction. Fertil Steril 62:204–205[Medline]
  2. Ozawa K, Mizunuma H, Ozawa H, Ibuki Y 1996 Recombinant human growth hormone acts on intermediate-sized follicles and rescues growing follicles from atresia. Endocr J 43:87–92[Medline]
  3. Childs GV, Unabia G, Rougeau D 1994 Cells that express luteinizing hormone (LH) and follicle-stimulating hormone (FSH) ß-subunit messenger ribonucleic acids during the estrous cycle: the major contributors contain LH, FSH, and/or growth hormone. Endocrinology 134:990–997[Abstract]
  4. Childs GV, Unabia G, Miller BT 1994 Cytochemical detection of gonadotropin-releasing hormone-binding sites on rat pituitary cells with luteinizing hormone, follicle-stimulating hormone, and growth hormone antigens during diestrous up-regulation. Endocrinology 134:1943–1951[Abstract]
  5. Harvey S, Baumbach WR, Sadeghi H, Sanders EJ 1993 Ultrastructural colocalization of growth hormone binding protein and pituitary hormones in adenohypophyseal cells of the rat. Endocrinology 133:1125–1130[Abstract]
  6. Shoham Z, Conway GS, Ostergaard H, Lahlou N, Bouchard P, Jacobs HS 1992 Cotreatment with growth hormone for induction of spermatogenesis in patients with hypogonadotropic hypogonadism. Fertil Steril 57:1044–1051[Medline]
  7. Laron Z 1993 Laron syndrome: from description to therapy. Endocrinologist 3:21–28
  8. Strobl JS, Thomas MJ 1994 Human growth hormone. Pharmacol Rev 46:1–34[Abstract]
  9. Zipf WB, Payne AH, Kelch RP 1978 Prolactin, growth hormone, and luteinizing hormone in the maitenance of testicular luteinizing hormone receptors. Endocrinology 103:595–600[Medline]
  10. Swerdloff RS, Odell WD 1977 Modulating influence of FSH, GH and prolactin on LH-stimulated testosterone secretion. In: Troen P, Nankin HR (eds) The Testis in Normal and Infertile Men. Raven Press, New York, pp 395–401
  11. Arsenijevic Y, Wehrenberg WB, Conz A, Eshkol A, Sizonenko PC, Aubert ML 1989 Growth hormone (GH) deprivation induced by passive immunization against rat GH-releasing factor delays sexual maturation in the male rat. Endocrinology 124:3050–3059[Abstract]
  12. Chandrashekar V, Bartke A 1998 The role of growth hormone in the control of gonadotropin secretion in adult male rats. Endocrinology 139:1067–1074[Abstract/Free Full Text]
  13. Chandrashekar V, Bartke A 1993 Induction of endogenous insulin-like growth factor-I secretion alters the hypothalamic-pituitary-testicular function in growth hormone-deficient adult dwarf mice. Biol Reprod 48:544–551[Abstract]
  14. Slabaugh MB, Lieberman ME, Rutledge JJ, Gorski J 1981 Growth hormone and prolactin synthesis in normal and homozygous Snell and Ames dwarf mice. Endocrinology 109:1040–1046[Abstract]
  15. Sornson MW, Wu W, Dasen JS, Flynn SE, Norman DJ, O’Connell SM, Gukovsky I, Carriere C, Ryan AK, Miller AP, Zuo L, Gleiberman AS, Andersen B, Beamer WG, Rosenfeld MG 1996 Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism. Nature 384:327–333[CrossRef][Medline]
  16. Zhou Y, Xu BC, Maheswari HG, He L, Reed M, Lozykowski M, Okada S, Cataldo L, Coschigamo K, Wagner TE, Baumann G, Kopchick JJ 1997 A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci USA 94:13215–13220[Abstract/Free Full Text]
  17. Eisen EJ, Fortman M, Chen WY, Kopchick JJ 1993 Effects of genetic background on growth of mice hemizygous for wild-type or dwarf mutated bovine growth hormone transgenes. Theor Appl Genet 87:161–169
  18. Chandrashekar V, Bartke A, Wagner TE 1988 Endogenous human growth hormone (GH) modulates the effect of gonadotropin-releasing hormone on pituitary function and the gonadotropin response to the negative feedback effect of testosterone in adult male transgenic mice bearing human GH gene. Endocrinology 123:2717–2722[Abstract]
  19. Dufau ML, Catt KJ 1971 Gonadotropin stimulation of testosterone production by the rat testis in vitro. Biochim Biophys Acta 252:574–579[Medline]
  20. Bowsher RB, Lee W, Apathy JM, O’Brien PJ, Ferguson AL, Henry DP 1991 Measurement of insulin-like growth factor-II in physiological fluids and tissues. I. An improved extraction procedure and radioimmunoassy for human and rat fluids. Endocrinology 128:805–814[Abstract]
  21. Breier BH, Gallaher BW, Gluckman PD 1991 Radioimmunoassay for insulin-like growth factor-I: solution to some potential problems and pitfalls. J Endocrinol 128:347–357[Abstract/Free Full Text]
  22. Shrenker P, Bartke A 1987 Effects of hyperprolactinemia on male sexual behaviour in the golden hamster and mouse. J Endocrinol 112:221–228[Abstract/Free Full Text]
  23. Huseby RA, Sores MJ, Talamantes F 1985 Ectopic pituitary grafts in mice: hormone levels, effects on fertility, and the development of adenomyosis uteri, prolactinomas, and mammary carcinomas. Endocrinology 116:1440–1448[Abstract]
  24. Chubb C 1987 Sexual behavior and fertility of little mice. Biol Reprod 37:564–569[Abstract]
  25. Palmiter RD, Brinster RL, Hammer RE, Trumbauer ME, Rosenfeld MG, Brinberg NC, Evans RM 1982 Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature 300:611–615[CrossRef][Medline]
  26. Behringer RR, Lewin TM, Quaife CJ, Palmiter RD, Brinster RL, D’Ercole AJ 1990 Expression of insulin-like growth factor I stimulates normal somatic growth in growth hormone-deficient transgenic mice. Endocrinology 127:1033–1040[Abstract]
  27. Bartke A, Lloyd CW 1970 The influence of pituitary homografts on the weight of the accessory reproductive organs in castrated male mice and rats and on mating behavior in male mice. J Endocrinol 46:313–320[Abstract/Free Full Text]
  28. Bartke A, Naar EM, Johnson L, May MR, Cecim M, Yun JS, Wagner TE 1992 Effects of expression of human or bovine growth hormone genes on sperm production and male reproductive performance in four lines of transgenic mice. J Reprod Fertil 95:109–118[Abstract/Free Full Text]
  29. Mathews LS, Hammer RE, Brinster RL, Palmiter RD 1988 Expression of insulin-like growth factor I in transgenic mice with elevated levels of growth hormone is correlated with growth. Endocrinology 123:433–437[Abstract]
  30. Jansson JO, Ekberg S, Isaksson OGP, Eden S 1984 Influence of gonadal steroids on age- and sex-related secretory patterns of growth hormone in the rat. Endocrinology 114:1287–1294[Abstract]
  31. Carmignac DF, Gabrielsson BG, Robinson IC 1993 Growth hormone binding protein in the rat: effects of gonadal steroids. Endocrinology 133:2445–2452[Abstract]
  32. Jansson JO, Eden S, Isaksson O 1983 Sites of action of testosterone and estradiol on longitudinal bone growth. J Physiol 243:E135–E140
  33. Chandrashekar V, Bartke A 1996 Influence of hypothalamus and ovary on pituitary function in transgenic mice expressing the bovine growth hormone gene and in growth hormone-deficient Ames dwarf mice. Biol Reprod 54:1002–1008[Abstract]
  34. Steger RW, Bartke A, Parkening TA, Collins T, Buonomo FC, Tang K, Wagner TE, Jun JS 1991 Effects of heterologous growth hormones on hypothalamic and pituitary function in transgenic mice. Neuroendocrinology 53:365–372[Medline]
  35. Kamberi IA, Mical RS, Porter JC 1971 Effect of anterior pituitary perfusion and intraventricular injection of catecholamines on prolactin release. Endocrinology 88:1012–1020[Medline]
  36. Moore KE 1987 Interaction between prolactin and dopaminergic neurons. Biol Reprod 36:47–58[Abstract]
  37. Klemcke HG, Bartke A 1981 Effects of chronic hyperprolactinemia in mice on plasma gonadotropin concentrations and testicular human chorionic gonadotropin binding sites. Endocrinology 108:1763–1768[Abstract]
  38. Bartke A, Morgan WW, Clayton RN, Banerji TK, Brodie AM, Parkening TA, Collins TJ 1987 Neuroendocrine studies in hyperprolactinemic male mice. J Endocrinol 112:215–220[Abstract/Free Full Text]
  39. Cheung CY 1983 Prolactin suppresses luteinizing hormone secretion and pituitary responsiveness to luteinizing hormone-releasing hormone by a direct action at the anterior pituitary. Endocrinology 113:632–638[Abstract]
  40. Garcia A, Herbon L, Barkan A, Papavasiliou S, Marshall JC 1985 Hyper-prolactinemia inhibits gonadotropin-releasing hormone (GnRH) stimulation of the number of pituitary GnRH receptors. Endocrinology 117:954–959[Abstract]
  41. Lewis CE, Fink G, Dow RC, Morris JF 1986 Hyperprolactinemia induced by pituitary isografts suppresses the priming effect of LH-releasing hormone in normal and hypogonadal mice. Neuroendocrinology 43:584–586[Medline]
  42. Lin T, Haskell J, Vinson N, Terracio L 1986 Characterization of insulin and insulin-like growth factor I receptors of purified Leydig cells and their role in steroidogenesis in primary culture: a comparative study. Endocrinology 119:1641–1647[Abstract]
  43. Kasson BG, Hsueh AJW 1987 Insulin-like growth factor-I augments gonadotropin-stimulated androgen biosynthesis by cultured rat testicular cells. Mol Cell Endocrinol 52:27–34[CrossRef][Medline]
  44. Lin T, Haskell J, Vinson N, Terracio L 1986 Direct stimulatory effects of insulin-like growth factor I on Leydig cell steroidogenesis in primary culture. Biochem Biophys Res Commun 137:950–956[CrossRef][Medline]
  45. Lin T, Wang D, Calkins JH, Guo H, Chi R, Housley PR 1990 Regulation of insulin-like growth factor-I messenger ribonucleic acid expression in Leydig cells. Mol Cell Endocrinol 73:147–152[CrossRef][Medline]
  46. Moore A, Chen CL, Davis JR, Morris ID 1993 Insulin-like growth factor-I mRNA expression in the interstitial cells of the testis. J Mol Endocrinol 11:319–324[Abstract/Free Full Text]
  47. Cailleau J, Vermeire S, Verhoeven G 1990 Independent control of the production of insulin-like growth factor I and binding proteins by cultured testicular cells. Mol Cell Endocrinol 69:79–89[CrossRef][Medline]
  48. Naville D, Chatelain P, Avallet O, Saez J 1990 Control of production of insulin-like growth factor-I by pig Leydig cells cultured alone or together. Cell-cell interactions. Mol Cell Endocrinol 70:217–224[CrossRef][Medline]
  49. Baker J, Hardy MP, Zhou J, Bondy C, Lupu F, Bellve AR, Efstratiadis A 1996 Effects of an Igf1 gene null mutation on mouse reproduction. Mol Endocrinol 10:903–918[Abstract]
  50. Breier BH, Vickers MH, Gravance CG, Casey PJ 1996 Growth hormone (GH) therapy markedly increases the motility of spermatozoa and the concentration of insulin-like growth factor-I in seminal vesicle fluid in the male GH-deficient dwarf mice. Endocrinology 137:4061–4064[Abstract]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chandrashekar, V.
Right arrow Articles by Kopchick, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chandrashekar, V.
Right arrow Articles by Kopchick, J. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals